Epogen (erythropoietin)
Executive Summary
Amgen reports that product sales for the third quarter ended Dec. 31 were $49.4 mil. compared to $674,000 a year ago. Epogen, approved in June 1989, is currently Amgen's only approved therapeutic product. Nine-month sales were $98.6 mil. Net income was $8 mil. and $12.7 mil. for the three months and nine months, respectively.
Amgen reports that product sales for the third quarter ended Dec.
31 were $49.4 mil. compared to $674,000 a year ago. Epogen,
approved in June 1989, is currently Amgen's only approved
therapeutic product. Nine-month sales were $98.6 mil. Net income
was $8 mil. and $12.7 mil. for the three months and nine months,
respectively. |